Skip to main content

Table 1 Summary of patients with epithelioid hemangioendothelioma treated with anti-angiogenic therapy

From: Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma—a suitable treatment option: case report and review of anti-angiogenic treatment options

First author (ref) No.pts. Median age Gender Treatment medications Response
Gaur S [6] 1 35 M Bevacizumab, Nab-Paclitaxel SD
Belmont [22] 1 41 M Bevacizumab, Carboplatin, Paclitaxel PR
Kim [15] 1 44 F Bevacizumab, Carboplatin, Paclitaxel PD
Lopes [16] 1 51 M Bevacizumab, Carboplatin, Etoposide PD
Mizota [23] 1 59 F Bevacizumab, Carboplatin, Paclitaxel PD
Ye [9] 1 44 F Bevacizumab, Carboplatin, Paclitaxel SD
Lazarus [24] 1 42 M Bevacizumab, Paclitaxel PD
1 42 M Carboplatin, Etoposide PD
Salech [25] 1 40 F Thalidomide PR
Raphael et al. [26] 1 53 F Thalidomide SD
Kassam et al. [27] 1 13 F Thalidomide PD
Bolke et al. [28] 1 47 M Thalidomide PD
Mascarenhas et al. [29] 1 52 M Thalidomide PR
Pallotti et al. [31] 1 73 M Lenalidomide SD
Sumrall et al. [30] 1 31 F Lenalidomide SD
Agulnik et al. [18] 2 NA NA Bevacizumab PR
1 NA NA Bevacizumab PD
4 NA NA Bevacizumab SD
Chevreau et al. [19] 5 NA NA Sorafenib SD
2 NA NA Sorafenib PR
8 NA NA Sorafenib PD
  1. PR partial response, PD progressive disease, SD stable disease